Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06681220
Title Biomarker Directed Trial of Temozolomide and PARP Inhibition in Relapsed SCLC (Relapsed SCLC)
Acronym Relapsed SCLC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors VA Office of Research and Development
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
VA Palo Alto Health Care System, Palo Alto, CA Palo Alto California 94304-1207 United States Details
VA Greater Los Angeles Healthcare System, West Los Angeles, CA West Los Angeles California 90073-1003 United States Details
Jesse Brown VA Medical Center, Chicago, IL Chicago Illinois 60612 United States Details
Richard L. Roudebush VA Medical Center, Indianapolis, IN Indianapolis Indiana 46202-2884 United States Details
Robley Rex VA Medical Center, Louisville, KY Louisville Kentucky 40206-1433 United States Details
VA Ann Arbor Healthcare System, Ann Arbor, MI Ann Arbor Michigan 48105-2303 United States Details
Minneapolis VA Health Care System, Minneapolis, MN Minneapolis Minnesota 55417-2309 United States Details
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE Omaha Nebraska 68105-1850 United States Details
Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC Salisbury North Carolina 28144 United States Details
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA Philadelphia Pennsylvania 19104-4551 United States Details
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA Pittsburgh Pennsylvania 15240 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field